<p>Truist Financial Corp 在最近向证券交易委员会（SEC）提交的文件中表示，在第四季度将其在 Emergent BioSolutions Inc.（纽约证券交易所代码：EBS - 免费报告）的股份减少了 40.9%。该基金在此期间出售了 59,003 股后，持有该生物制药公司 85,193 股股票。Truist Financial Corp 在最近一个季度末持有的 Emergent BioSolutions 的股份价值 814,000 美元，占其总股份的 0.16%。</p>
<p>获取 <strong>Emergent BioSolutions</strong> 警报：</p>
<ul>
<li>在市场轮动持续的情况下，关注这 4 只超买股票</li>
</ul>
<p>其他对冲基金最近也调整了对该公司的持股。Stifel Financial Corp 在第三季度购买了 Emergent BioSolutions 的新股份，价值约 96,000 美元。FORA Capital LLC 在第三季度购买了 Emergent BioSolutions 的新股份，价值约 103,000 美元。Landscape Capital Management L.L.C. 在第三季度购买了 Emergent BioSolutions 的新股份，价值约 141,000 美元。Entropy Technologies LP 在第三季度购买了 Emergent BioSolutions 的新股份，价值约 155,000 美元。最后，B. Riley Wealth Advisors Inc. 在第三季度购买了 Emergent BioSolutions 的新股份，价值约 295,000 美元。78.40% 的股票由机构投资者和对冲基金持有。</p>
<h2>Emergent BioSolutions 股票表现</h2>
<p>Emergent BioSolutions 股票周五开盘价为 7.46 美元。该公司的市值为 4.0394 亿美元，市盈率为 -1.82，贝塔值为 1.62。该公司的 50 日移动平均价格为 9.54 美元，200 日移动平均价格为 9.06 美元。该公司的债务与股本比率为 1.30，流动比率为 2.88，速动比率为 1.47。Emergent BioSolutions Inc. 的 12 个月最低价为 1.82 美元，最高价为 15.10 美元。</p>
<h2>华尔街分析师观点</h2>
<p>EBS 已成为几份研究报告的主题。Benchmark 在 11 月 7 日的报告中将 Emergent BioSolutions 的目标股价从 8.00 美元上调至 12.00 美元，并给予该公司 &#34;买入&#34; 评级。StockNews.com 在 2 月 17 日的报告中将 Emergent BioSolutions 的评级从 &#34;持有&#34; 上调至 &#34;买入&#34;。最后，HC Wainwright 在 1 月 21 日的报告中重申了 &#34;买入&#34; 评级，并对 Emergent BioSolutions 的目标股价设定为 15.00 美元。</p>
<p><strong>查看我们对 Emergent BioSolutions 的最新股票分析</strong></p>
<h2>Emergent BioSolutions 公司简介</h2>
<p>（免费报告）</p>
<p>Emergent BioSolutions Inc. 是一家生命科学公司，提供针对美国意外、故意和自然发生的公共健康威胁的应急准备和响应解决方案。该公司提供 NARCAN 鼻用喷雾剂用于已知或疑似阿片类药物过量的紧急治疗；Vaxchora 疫苗用于预防霍乱；Vivotif 疫苗用于口服给药以预防伤寒；Anthrasil 用于吸入性炭疽的治疗；BioThrax，一种炭疽疫苗；CYFENDUS 用于在怀疑或确认接触炭疽芽孢杆菌后进行疾病的暴露后预防；以及 Raxibacumab 注射剂用于吸入性炭疽的治疗和预防。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，而非 Emergent BioSolutions</li>
<li>如何购买股票：初学者的逐步指南</li>
<li>Autodesk 为投资者设计的价值：上升趋势将持续</li>
<li>除了喝咖啡，还有 3 种投资咖啡的方法</li>
<li>安海斯 - 布希股票反弹——啤酒之王回归了吗？</li>
<li>什么是股票市场指数，如何使用它们？</li>
<li>MarketBeat 周回顾 – 02/24 - 02/28</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVCUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVCUw"/></p>
<p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Emergent BioSolutions 吗？</h2>
<p>在你考虑 Emergent BioSolutions 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Emergent BioSolutions 并不在名单上。</p>
<p>虽然 Emergent BioSolutions 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

<p>Truist Financial Corp 在第四季度将其在 Emergent BioSolutions Inc. (NYSE:EBS) 的持股减少了 40.9%，在出售了 59,003 股后，现持有 85,193 股。该公司的市值为 814,000 美元。其他对冲基金也增加了他们的持仓。Emergent 的股票开盘价为 7.46 美元，市值为 4.0394 亿美元，市盈率为 -1.82。分析师们提高了价格目标，Benchmark 将其从 8.00 美元上调至 12.00 美元，并维持 “买入” 评级</p>

<p>Truist Financial Corp reduced its position in shares of Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 40.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 85,193 shares of the biopharmaceutical company's stock after selling 59,003 shares during the period. Truist Financial Corp owned 0.16% of Emergent BioSolutions worth $814,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Truist Financial Corp 在最近向证券交易委员会（SEC）提交的文件中表示，在第四季度将其在 Emergent BioSolutions Inc.（纽约证券交易所代码：EBS - 免费报告）的股份减少了 40.9%。该基金在此期间出售了 59,003 股后，持有该生物制药公司 85,193 股股票。Truist Financial Corp 在最近一个季度末持有的 Emergent BioSolutions 的股份价值 814,000 美元，占其总股份的 0.16%。</p>
</div><p>Get <strong>Emergent BioSolutions</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Emergent BioSolutions</strong> 警报：</p>
</div><ul>
<li>Watch These 4 Overbought Stocks As Market Rotation Continues</li>
</ul>
<div class="lb-trans"><ul>
<li>在市场轮动持续的情况下，关注这 4 只超买股票</li>
</ul>
</div><p>Other hedge funds also recently modified their holdings of the company. Stifel Financial Corp purchased a new position in shares of Emergent BioSolutions during the 3rd quarter worth about $96,000. FORA Capital LLC purchased a new position in shares of Emergent BioSolutions during the 3rd quarter worth about $103,000. Landscape Capital Management L.L.C. purchased a new position in shares of Emergent BioSolutions during the 3rd quarter worth about $141,000. Entropy Technologies LP purchased a new position in shares of Emergent BioSolutions during the 3rd quarter worth about $155,000. Finally, B. Riley Wealth Advisors Inc. purchased a new position in shares of Emergent BioSolutions during the 3rd quarter worth about $295,000. 78.40% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他对冲基金最近也调整了对该公司的持股。Stifel Financial Corp 在第三季度购买了 Emergent BioSolutions 的新股份，价值约 96,000 美元。FORA Capital LLC 在第三季度购买了 Emergent BioSolutions 的新股份，价值约 103,000 美元。Landscape Capital Management L.L.C. 在第三季度购买了 Emergent BioSolutions 的新股份，价值约 141,000 美元。Entropy Technologies LP 在第三季度购买了 Emergent BioSolutions 的新股份，价值约 155,000 美元。最后，B. Riley Wealth Advisors Inc. 在第三季度购买了 Emergent BioSolutions 的新股份，价值约 295,000 美元。78.40% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Emergent BioSolutions Stock Performance</h2>
<div class="lb-trans"><h2>Emergent BioSolutions 股票表现</h2>
</div><p>Emergent BioSolutions stock opened at $7.46 on Friday. The company has a market cap of $403.94 million, a PE ratio of -1.82 and a beta of 1.62. The company has a fifty day moving average price of $9.54 and a two-hundred day moving average price of $9.06. The company has a debt-to-equity ratio of 1.30, a current ratio of 2.88 and a quick ratio of 1.47. Emergent BioSolutions Inc. has a 12 month low of $1.82 and a 12 month high of $15.10.</p>
<div class="lb-trans"><p>Emergent BioSolutions 股票周五开盘价为 7.46 美元。该公司的市值为 4.0394 亿美元，市盈率为 -1.82，贝塔值为 1.62。该公司的 50 日移动平均价格为 9.54 美元，200 日移动平均价格为 9.06 美元。该公司的债务与股本比率为 1.30，流动比率为 2.88，速动比率为 1.47。Emergent BioSolutions Inc. 的 12 个月最低价为 1.82 美元，最高价为 15.10 美元。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>EBS has been the topic of several research reports. Benchmark raised their price target on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the company a &#34;buy&#34; rating in a report on Thursday, November 7th. StockNews.com upgraded shares of Emergent BioSolutions from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Monday, February 17th. Finally, HC Wainwright restated a &#34;buy&#34; rating and issued a $15.00 price target on shares of Emergent BioSolutions in a report on Tuesday, January 21st.</p>
<div class="lb-trans"><p>EBS 已成为几份研究报告的主题。Benchmark 在 11 月 7 日的报告中将 Emergent BioSolutions 的目标股价从 8.00 美元上调至 12.00 美元，并给予该公司 &#34;买入&#34; 评级。StockNews.com 在 2 月 17 日的报告中将 Emergent BioSolutions 的评级从 &#34;持有&#34; 上调至 &#34;买入&#34;。最后，HC Wainwright 在 1 月 21 日的报告中重申了 &#34;买入&#34; 评级，并对 Emergent BioSolutions 的目标股价设定为 15.00 美元。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on Emergent BioSolutions</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Emergent BioSolutions 的最新股票分析</strong></p>
</div><h2>Emergent BioSolutions Profile</h2>
<div class="lb-trans"><h2>Emergent BioSolutions 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.</p>
<div class="lb-trans"><p>Emergent BioSolutions Inc. 是一家生命科学公司，提供针对美国意外、故意和自然发生的公共健康威胁的应急准备和响应解决方案。该公司提供 NARCAN 鼻用喷雾剂用于已知或疑似阿片类药物过量的紧急治疗；Vaxchora 疫苗用于预防霍乱；Vivotif 疫苗用于口服给药以预防伤寒；Anthrasil 用于吸入性炭疽的治疗；BioThrax，一种炭疽疫苗；CYFENDUS 用于在怀疑或确认接触炭疽芽孢杆菌后进行疾病的暴露后预防；以及 Raxibacumab 注射剂用于吸入性炭疽的治疗和预防。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Emergent BioSolutions</li>
<li>How to buy stock: A step-by-step guide for beginners</li>
<li>Autodesk Designs Value for Investors: Uptrend Set to Continue</li>
<li>3 Ways To Invest In Coffee, Other Than Drinking It</li>
<li>Anheuser-Busch Stock Rallies—Is the King of Beers Back?</li>
<li>What is a Stock Market Index and How Do You Use Them?</li>
<li>MarketBeat Week in Review – 02/24 - 02/28</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而非 Emergent BioSolutions</li>
<li>如何购买股票：初学者的逐步指南</li>
<li>Autodesk 为投资者设计的价值：上升趋势将持续</li>
<li>除了喝咖啡，还有 3 种投资咖啡的方法</li>
<li>安海斯 - 布希股票反弹——啤酒之王回归了吗？</li>
<li>什么是股票市场指数，如何使用它们？</li>
<li>MarketBeat 周回顾 – 02/24 - 02/28</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVCUw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=EBS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Emergent BioSolutions Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Emergent BioSolutions 吗？</h2>
</div><p>Before you consider Emergent BioSolutions, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Emergent BioSolutions 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Emergent BioSolutions wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Emergent BioSolutions 并不在名单上。</p>
</div><p>While Emergent BioSolutions currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Emergent BioSolutions 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Emergent BioSolutions Inc. (NYSE:EBS) 的股票被 Truist Financial Corp 出售